NR1H4 and primary biliary cholangitis: Some recent developed FXR agonist pharmacological agents have beenreported to have promising results in reducing liver damage in treatingnon-alcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC)diseases4,5.